AC Camargo Cancer Center
AC Camargo Cancer Center
São Paulo, 01509-001
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Natasha Carvalho
Mauro DS Donadio
Rachel SP Riechelmann
Marcelle G Cesca
Open studies
Breast Cancer
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer - HER2Cell - AC Camargo Cancer CenterSee more
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) - VIKTORIA-1 - Celcuity, Inc.See more
Multiple myeloma
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment - MonumenTAL-3 - Janssen Research & Development, LLCSee more
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma - MajesTEC-9 - Janssen Research & Development, LLCSee more
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4 - Janssen PharmaceuticaSee more
Bladder Cancer
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) - SunRISe-5 - Janssen Research & Development, LLCSee more
Lung cancer
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) - Merck Sharp & Dohme LLCSee more
Myeloproliferative syndromes
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment - MYF3001 - Geron CorporationSee more
Non-Hodgkin Lymphoma
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - EPCORE DLBCL-2 - AbbVieSee more
Ovarian cancer
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention - TUBA-WISP-II - University Medical Center NijmegenSee more
